Shares of Unichem Labs were trading in the green and 2% higher on 5 December after the company sold its stake in Optimus Drug to Sekhmet Pharmaventures for a total consideration of Rs 67.47 crore.

In its regulatory filing, the company said that it has divested 4,918 equity shares representing a 0.02% stake in Optimus Drugs, which have a carrying value of Rs 0.29 crore in the company’s books.

This is the company’s second trench of divestment of Optimus Drugs. They divested a 19.97% stake in Optimus Drugs to Sekhmet Pharmaventures on a fully diluted basis in the first tranche for a total value of Rs 270.99 crore.

On 21 September, Ipca Laboratories acquired a 1,35,79,571 equity shares representing 19.29% stake of the company for an average price of Rs 440 per share, taking the total transaction to Rs 597.50 crore.

Through this stake purchase, Unichem Labs has become a subsidiary of Ipca Laboratories, which holds 52.67% stake in total.

The company has several pharma products that address the needs of relevant and growing therapeutic areas, including cardiology, gastroenterology, neurology, anti-bacterial, psychiatry, anti-infectives and pain management.

At 2:57 pm, the shares of Unichem Labs were trading 1.27% higher at Rs 425.05 on NSE.